ADIL
ADIAL PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.62
+3.72%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.54
From 52W high−61.89%
Volume12085.00
Market cap$10.62M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.54
From 52W high
−61.89%
Volume
12085.00
Market cap
$10.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
42.0
MomentumView details →
1D Return
+3.72%
YTD Return
−34.18%
SummaryUpdated Jun 1, 2026
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Charlottesville, Virginia. The company went public in July 2018 and focuses on developing therapeutic treatments for addiction and related disorders. Adial is currently advancing its lead drug candidate through late-stage clinical trials, representing a specialized approach to addressing substance use disorders through targeted pharmaceutical interventions.
Similar companies
Latest newsMore news →
Adial Pharmaceuticals amended its Note Exchange Agreement with former Azora noteholders to remove the penalty provision and add a lock-up on shares issuable upon exercise of the Initial Closing Noteholder Pre-Funded Warrants.33d agoAdial Pharmaceuticals amended its Securities Purchase Agreement with PIPE investors to remove the penalty provision and add a lock-up on shares issuable upon exercise of the Initial Closing PIPE Pre-Funded Warrants.33d agoAdial Pharmaceuticals granted an option to purchase 307,814 shares of common stock at $5.76 per share as a material inducement to employment, exempt under Section 4(a)(2) of the Securities Act and Regulation D.56d ago